These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 8637514)

  • 21. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis.
    Rice TW; Wheeler AP; Bernard GR; Vincent JL; Angus DC; Aikawa N; Demeyer I; Sainati S; Amlot N; Cao C; Ii M; Matsuda H; Mouri K; Cohen J
    Crit Care Med; 2010 Aug; 38(8):1685-94. PubMed ID: 20562702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002).
    Watson D; Grover R; Anzueto A; Lorente J; Smithies M; Bellomo R; Guntupalli K; Grossman S; Donaldson J; Le Gall JR;
    Crit Care Med; 2004 Jan; 32(1):13-20. PubMed ID: 14707555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of the effects of TNF in renal allograft recipients using recombinant human dimeric tumor necrosis factor receptors.
    Eason JD; Wee S; Kawai T; Hong HZ; Powelson JA; Widmer MB; Cosimi AB
    Transplantation; 1995 Jan; 59(2):300-5. PubMed ID: 7839455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock.
    Stephens DP; Thomas JH; Higgins A; Bailey M; Anstey NM; Currie BJ; Cheng AC
    Crit Care Med; 2008 Feb; 36(2):448-54. PubMed ID: 18216600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical evaluation and radiological observation of recombinant human tumor necrosis factor receptor-Fc fusion protein in treatment of active ankylosing spondylitis].
    Pan XY; Li J; Pang J; Dai SH; Chen WG
    Zhonghua Yi Xue Za Zhi; 2008 May; 88(20):1408-11. PubMed ID: 18953881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002).
    Bakker J; Grover R; McLuckie A; Holzapfel L; Andersson J; Lodato R; Watson D; Grossman S; Donaldson J; Takala J;
    Crit Care Med; 2004 Jan; 32(1):1-12. PubMed ID: 14707554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Etanercept or intravenous immunoglobulin attenuates expression of genes involved in post-myocardial infarction remodeling.
    Gurantz D; Yndestad A; Halvorsen B; Lunde OV; Omens JH; Ueland T; Aukrust P; Moore CD; Kjekshus J; Greenberg BH
    Cardiovasc Res; 2005 Jul; 67(1):106-15. PubMed ID: 15949474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
    Gorman JD; Sack KE; Davis JC
    N Engl J Med; 2002 May; 346(18):1349-56. PubMed ID: 11986408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adrenal insufficiency occurring during septic shock: incidence, outcome, and relationship to peripheral cytokine levels.
    Soni A; Pepper GM; Wyrwinski PM; Ramirez NE; Simon R; Pina T; Gruenspan H; Vaca CE
    Am J Med; 1995 Mar; 98(3):266-71. PubMed ID: 7872343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial.
    Darenberg J; Ihendyane N; Sjölin J; Aufwerber E; Haidl S; Follin P; Andersson J; Norrby-Teglund A;
    Clin Infect Dis; 2003 Aug; 37(3):333-40. PubMed ID: 12884156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemofiltrastion does not influence early S-100B serum levels in septic shock patients receiving stress doses of hydrocortisone or placebo.
    Mussack T; Briegel J; Schelling G; Jochum M
    Eur J Med Res; 2005 Jan; 10(1):11-7. PubMed ID: 15737948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.
    Neurology; 1999 Aug; 53(3):457-65. PubMed ID: 10449104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A recombinant tumor necrosis factor-alpha p80 receptor:Fc fusion protein decreases circulating bioactive tumor necrosis factor-alpha but not lung injury or mortality during immunosuppression-related gram-negative bacteremia.
    Lechner AJ; Johanns CA; Matuschak GM
    J Crit Care; 1997 Mar; 12(1):28-38. PubMed ID: 9075062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis.
    Moreland LW; Margolies G; Heck LW; Saway A; Blosch C; Hanna R; Koopman WJ
    J Rheumatol; 1996 Nov; 23(11):1849-55. PubMed ID: 8923355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoglobulin G treatment of postcardiac surgery patients with score-identified severe systemic inflammatory response syndrome--the ESSICS study.
    Werdan K; Pilz G; Müller-Werdan U; Maas Enriquez M; Schmitt DV; Mohr FW; Neeser G; Schöndube F; Schäfers HJ; Haverich A; Fraunberger P; Andersson J; Kreuzer E; Thijs LG;
    Crit Care Med; 2008 Mar; 36(3):716-23. PubMed ID: 18091548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.
    Lovell DJ; Giannini EH; Reiff A; Cawkwell GD; Silverman ED; Nocton JJ; Stein LD; Gedalia A; Ilowite NT; Wallace CA; Whitmore J; Finck BK
    N Engl J Med; 2000 Mar; 342(11):763-9. PubMed ID: 10717011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study.
    de Kleijn ED; de Groot R; Hack CE; Mulder PG; Engl W; Moritz B; Joosten KF; Hazelzet JA
    Crit Care Med; 2003 Jun; 31(6):1839-47. PubMed ID: 12794428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor necrosis factor receptor: Fc fusion protein does not improve septic shock and may increase mortality in human.
    Atallah AN
    Sao Paulo Med J; 1996; 114(3):1151. PubMed ID: 9181744
    [No Abstract]   [Full Text] [Related]  

  • 40. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group.
    Abraham E; Anzueto A; Gutierrez G; Tessler S; San Pedro G; Wunderink R; Dal Nogare A; Nasraway S; Berman S; Cooney R; Levy H; Baughman R; Rumbak M; Light RB; Poole L; Allred R; Constant J; Pennington J; Porter S
    Lancet; 1998 Mar; 351(9107):929-33. PubMed ID: 9734938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.